ALN-6400 Phase 1 (HV) and Phase 2 HHT results in 2H 2026
Alnylam expects to report results from its Phase 1/2 study of ALN-6400 for Von Willebrand disease (bleeding disorders) in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Alnylam Pharmaceuticals, Inc. ALNY
- Drug
- ALN-6400
- For
- Von Willebrand disease (bleeding disorders)
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- H2 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- existing entry ALNY|readout|2026-H2 'ALN-6400 Ph1/2 VWD' — Q2 2026 release specifies the 2H 2026 readouts are Phase 1 in healthy volunteers and Phase 2 in HHT; the VWD Phase 2 was only just initiated in Q2 2026.
- Checked
- Checked by a person when it was added
- Source: investors.alnylam.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ALNY headlines on this site
Alnylam expects to report results from its Phase 1 study of ALN-2232 for Obesity and weight management in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
More details
- Entry
- ALN-2232 Phase 1 obesity data · Clinical trial results (readout / topline data)
- Drug
- ALN-2232
- For
- Obesity and weight management
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Alnylam Q2 2026 press release guides Phase 1 results in the second half of 2026 — first clinical look at Alnylam's RNAi approach in obesity.
- Checked
- Checked by a person when it was added
- Verify it
- Source: investors.alnylam.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- ALNY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Nov 2026 (no exact date yet) whether to approve Alnylam’s Cemdisiran for Generalized myasthenia gravis (anti-AChR+). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
More details
- Entry
- PDUFA cemdisiran gMG (Regeneron-led; Alnylam royalty) · FDA decision due (PDUFA date)
- Drug
- Cemdisiran
- For
- Generalized myasthenia gravis (anti-AChR+)
- Stage
- NDA / Priority Review
- When
- Nov 2026 · the company gave a window, not a day
- Source note
- Alnylam July 30, 2026 Q2 release; same event as REGN|pdufa|2026-11 but attached to ALNY (Alnylam-discovered, Regeneron-led; EC decision anticipated H2 2027).
- Checked
- Checked by a person when it was added
- Verify it
- Source: investors.alnylam.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- ALNY headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page